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S U M M A R Y 
A delayed evaluation of two groups of patients with paracoccidioidomycosis 
was carried out. Both groups were treated with amphotericin B, "but one of 
them was submitted to maintenance treatment with sulfonamides. Statistical 
analysis showed that treatment is more effective when patients are maintained 
with sulfonamide drugs. 
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I N T R O D U C T I O N MATERIAL AND METHODS 
Amphotericin B and the sulfonamides are 
drugs that have been effectively used in the 
treatment of paracoccidioidomycosis, either se-
parately or in association. 
Many reports have been published both in 
Brazil and abroad on the therapeutic results 1-
2.5,7.8,9,10,11,12 and the side effects 3,4,14 of these 
drugs. SAMPAIO13 and DILLON6 concluded 
cn the superiority of amphotericin B when 
compared to separately administered sulfona-
mides. No studies, however, have been carried 
out to compare the therapeutic results obtained 
with amphotericin B alone and associated with 
sulfonamides for the maintenance treatment of 
paracoccidioidomycosis, and the present study 
was undertaken with the objective to make 
such a comparison. 
The study was carried out on two groups 
of patients with paracoccidioidomycosis. The 
first consisted of 69 patients treated with am-
photericin B only at the University Hospital of 
the Faculty of Medicine of the University of 
São Paulo from 1958 to 1963, and studied by 
SAMPAIO (1960) and DILLON (1972). The se-
cond consisted of 42 patients treated with am-
photericin B and submitted to maintenance 
treatment with sulfonamides at the University 
Hospital of the Faculty of Medicine of Botu-
catu from 1968 to 1982. 
The patients were grouped by phases on 
the basis of time without treatment. Thus, Pha-
se 1 = less than 1 year; Phase 2 = 1 to 2 years; 
Phase 3 = 2 to 5 years; Phase 4 = 5 to 9 years; 
Phase 5 = 9 to 14 years. Patients were evaluated 
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on the basis of clinical, radiologic and serologic 
data, distributed among the following classes: 
FCRS = free from clinical, radiologic or se­
rologic lesions SA = with serologic activity on­
ly; WCRS = with clinical, radiologic and sero­
logic lesions; DWSL = death with specific le­
sions. 
The groups were evaluated for homogenei­
ty in terms of sex, age range, organic involve­
ment and number of amphotericin B series 
by the X2 test 1 6 . For the last similarity factor, 
i.e., the total dose of amphotericin B adminis­
tered, and for comparison of the treatments, 
we Utilized the KOLMOGOROV-SMIRNOV i' 
test for two independent samples and deter­
mined the distribution of the two groups in 
terms of classes for each phase. In these tests, 
we consider F6 = P4 + F5 and X = 0.05. 
To compare treatments at each phase, sco­
res were given to each class according to the 
general condition of each patient: class 1 = 8 
points; class 2 = 4 points; class 3 = 2 points; 
class 4 = 1 point. An index was obtained by 
summing the number of cases in each class 
multiplied by the respective points. The re­
sults were analyzed statistically by binomial 
test«. 
RESULTS AND DISCUSSION 
The two groups were homogenous in terms 
of sex, age range, organic involvement, dose 
of amphotericin B (number of series and total 
dose administered), as shown in Tables I, II, 
III, I Vand V, respectively. 
Table VI shows the sulfonamides used for 
the maintenance treatment of group II. 
The statistical analyses for treatment com­
parison were based on the data in Table VII, 
which shows distribution by phase and class 
for the patients in both groups, except for pha­
se 2 for which no comparison was possible be­
cause the data obtained were identical. 
Difference between groups was observed 
in phases 1 and 2 owing to the concentration 
of patients submitted to treatment 2 in classes 
FCES and SA. No significant difference in pa-
tient distribution was observed in phase 6. 
However, if the same proportions of occurren-
ce were maintained and the number of patients 
observed were increased, difference between 
treatments would also be obtained at the ex-
pense of treatment 2. 
The indices obtained were always higher for 
treatment 2 at all phases (Table VIII), with an 
even greater difference starting from phase 3 
(2 to 4 years). The statistical differences observ-
ed were due to the larger number of patients 
submitted to treatment 2 in classes WCRS and 
SA, which indicate better clinical conditions 
at all phases of follow-up, and were even more 
noticeable after 2 years of patients cured by 
treatment 2 is higher than cured by treat-
ment 1. 
Thus we conclude that the use of amphote-
ricin B and maintenance treatment with sulfo-
namide derivatives of paracoccidioidomycosis 
is more effective than the use of amphotericin 
B alone, even at high doses. 
RESUMO 
Resultados tardios do tratamento da paracoc¬ 
cidioidomicose com anfotericina B mais sul-
famídicos "versus" anfotericina B isoladamente 
Os Autores avaliam tardiamente dois gru-
pos de doentes de paracoccidioidomicose. Am-
bos foram tratados com anfotericina B, tendo 
um deles feito tratamento de manutenção com 
sulfamídicos. 
Através de análises estatísticas comprovam 
a maior eficácia do tratamento, quando se faz 
a manutenção com sulfamídicos. 
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